Stocks
Medivation, Inc.MDVN
YHDHealthcareBiotechnology
Developer of oncology therapeutics focused on treatments for serious cancers, best known for the prostate cancer drug Xtandi (enzalutamide). The company generated revenue primarily through collaboration and royalty arrangements tied to its oncology portfolio, drawing investor attention to clinical t...
Congressional Interest in Medivation, Inc. (MDVN)
2 members of Congress have disclosed 2 trades in Medivation, Inc. (MDVN), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 2 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
2
Unique Politicians
2
Buys
0
Sells
2
Who in Congress Is Trading MDVN?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2016-09-12 | K. Michael Conaway | sell | $1K – $15K |
| 2015-05-27 | Thomas MacArthur | sell | $1K – $15K |